ELAN

EX-99.1

2 elanco-20260630exhibit991.htm

EXHIBIT 99.1 - PRESS RELEASE DATED AUGUST 5, 2026

Document

Exhibit 99.1

FOR IMMEDIATE RELEASE

Investor Contact: Tiffany Kanaga (765) 740-0314 or tiffany.kanaga@elancoah.com

Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com

Elanco Animal Health Reports Second Quarter 2026 Results

Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target

•Second Quarter 2026 Financial Results:

◦Revenue of $1,368 million, an increase of 10% year-over-year; 8% organic constant currency growth

◦Reported Net Income of $54 million, Adjusted Net Income of $174 million

◦Adjusted EBITDA of $288 million; Adjusted EBITDA Margin of 21.2%

◦Reported EPS of $0.11, Adjusted EPS of $0.34

◦Net leverage ratio of 3.1x Adjusted EBITDA

•Full Year 2026 Guidance:

◦Raising innovation revenue target to $1.25 billion

◦Raising revenue guidance to $5.09 billion to $5.14 billion, or 6% to 7% organic constant currency growth

◦Raising Adjusted EBITDA to $1.01 billion to $1.035 billion, a year-over-year increase of 13% at midpoint

◦Raising Adjusted EPS to $1.10 to $1.16, a year-over-year increase of 20% at midpoint

◦Improving year-end net leverage ratio target to approximately 3.0x Adjusted EBITDA

Indianapolis, IN (August 5, 2026) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the second quarter of 2026, provided guidance for the third quarter of 2026, and updated guidance for the full year 2026.

"Elanco’s second quarter results demonstrate our momentum and leadership in the attractive animal health industry," stated Jeff Simmons, President and CEO of Elanco. "Organic constant currency revenue growth of 8% was led by U.S. Pet Health and U.S. Farm Animal each up 11%. We saw strong contributions from both price and volume, as consumer demand for our basket of innovation drove market share gains and stabilized our base business. Zenrelia — our newest blockbuster — was the single largest contributor to global Elanco growth, closely followed by Credelio Quattro. As we are raising our top- and bottom-line full-year outlook, including faster than planned margin expansion and net debt deleverage, our consistent delivery demonstrates our Innovation Portfolio Productivity (IPP) strategy is working. We also continue to expect a sustainable mid-single digit CAGR in animal health through the global drivers that matter most in pets and protein. Elanco is well positioned through our differentiated innovation, our comprehensive portfolio, our diverse go-to-market model, and our commercial execution, creating durable value for our customers, our shareholders, and the industry."

Select Business Highlights Since the Last Earnings Call

•Zenrelia™ achieved blockbuster status July YTD; efficacy driving use in approximately 18,000 U.S. clinics; U.S. JAK market share up 9 points year-over-year with gains versus Q1**; up to 40%+ JAK market share in key European markets, outperforming the competitive entrant***

•Credelio Quattro™ accelerated dollar share gains of broad-spectrum sales out U.S. vet clinics in Q2, up 4 points versus Q1**; penetrated over 50% of the U.S. clinic base, up approximately 3,000 clinics representing 10 points versus Q1; launched in Australia, Canada, and Japan to date

1

•Befrena™ shipped to nearly 1,400 U.S. clinics to date; ramping capacity to meet high customer demand 2x above expectations, with weekly increases in supply

•Global ruminants was Elanco's fastest growing species, up 12% in the quarter on an organic constant currency basis or 17% including AHV International and FX, as innovation fortified the company's beef and dairy portfolio

•The company released its 2025 Impact Report, celebrating Elanco's leadership with purpose, and culture of 'Going Beyond' for animals, customers, society, and its people

**Per Kynetec data

***Internal estimates based on multiple data sources

Financial Results

Second Quarter Results

(dollars in millions, except per share amounts) 20262025Change (%) Organic CC Growth (1) (%)

Pet Health$718$64312 %11 %

Farm Animal$633$5839 %5 %

Cattle$313$26817 %12 %

Poultry$223$2154 %2 %

Swine$97$100(3)%(4)%

Contract Manufacturing and Other (2) $17$1513 %

Total Revenue$1,368$1,24110 %8 %

Gross Profit$798$71312 %

Reported Net Income$54$11391 %

Adjusted EBITDA$288$23821 %

Reported EPS$0.11$0.02450 %

Adjusted EPS$0.34$0.2631 %

(1) Organic CC Growth represents revenue growth excluding royalty revenue that was sold to a third party, the impact of foreign exchange rates, and revenue attributable to AHV International B.V., which was acquired on April 30, 2026.

(2) Primarily represents revenue from arrangements in which we manufacture products on behalf of a third party and royalty revenue. Royalty revenue sold to a third party, to which we are no longer entitled but is still required to be recognized as revenue under GAAP, totaled $9 million and $4 million f

EX-99.1

2 elanco-20260331exhibit991.htm

EXHIBIT 99.1 PRESS RELEASE DATED MAY 6, 2026

Document

Exhibit 99.1

FOR IMMEDIATE RELEASE

Investor Contact: Tiffany Kanaga (765) 740-0314 or tiffany.kanaga@elancoah.com

Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com

Elanco Animal Health Reports First Quarter 2026 Results

Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target

•First Quarter 2026 Financial Results:

◦Revenue of $1,371 million, an increase of 15% year-over-year; 10% organic constant currency growth

◦Reported Net Income of $57 million, Adjusted Net Income of $204 million

◦Adjusted EBITDA of $334 million; Adjusted EBITDA Margin of 24.5%

◦Reported EPS of $0.11, Adjusted EPS of $0.40

◦Net leverage ratio of 3.5x Adjusted EBITDA

•Full Year 2026 Guidance:

◦Raising innovation revenue target to $1.2 billion

◦Raising revenue guidance to $5,010 million to $5,085 million, or 5% to 7% organic constant currency growth

◦Raising Adjusted EBITDA to $975 million to $1,005 million, a year-over-year increase of 10% at midpoint

◦Raising Adjusted EPS of $1.03 to $1.09, a year-over-year increase of 13% at midpoint

◦Improving year-end net leverage ratio target to 3.0x to 3.2x Adjusted EBITDA

Indianapolis, IN (May 6, 2026) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the first quarter of 2026, provided guidance for the second quarter of 2026, and updated guidance for the full year 2026.

"Elanco's strong first quarter results demonstrate the significant momentum of our innovation-led strategy," said Jeff Simmons, President and CEO of Elanco. "Organic constant currency revenue growth of 10% reflects outperformance across our diverse portfolio, including Zenrelia reaching trailing 4-quarter blockbuster status, and Credelio Quattro achieving accelerating market share gains. All major species grew, driven by our basket of innovation and growth in our base business. We are improving our full year guidance across all key metrics, as our consistent execution is creating more ways for Elanco to win in this durable, attractive animal health industry."

Select Business Highlights Since the Last Earnings Call

•Credelio Quattro™ accelerated dollar share gains of broad-spectrum sales out of U.S. vet clinics in Q1, up 3 points versus Q4**; penetrated over 40% of the U.S. clinic base; 53% share in U.S. clinics that carry Quattro, up 13 points in Q1 versus Q4**; launched in Australia and approved in Canada, both in April

•Zenrelia™ achieved trailing 4-quarter blockbuster status; over 2 million dogs have been treated; efficacy driving use in over 50% of U.S. clinics with U.S. JAK market share up 5 points versus Q4**; over 50% share of JAK market in Brazil, over 35% share in Japan, and high-teens to 30%+ JAK market share in key European markets***

•Befrena™ phased launch approach on track, with product already shipped to early experience influencers and in use, and commercialization in the U.S. expected in Q2

•Added Costco and Dollar General as new retail customers for parasiticides in the U.S.

•Advantage® Collar for Dogs launched in April, providing four-month protection against fleas and ticks, available at pet specialty, dollar, grocery, and mass retailers

1

•Closed the previously announced acquisition of AHV International on April 30th

**Per Kynetec data

***Internal estimates based on multiple data sources

Financial Results

First Quarter Results

(dollars in millions, except per share amounts) 20262025Change (%) Organic CC Growth (1) (%)

Pet Health$710$63512 %7 %

Farm Animal$642$54618 %13 %

Cattle$316$27216 %13 %

Poultry$230$18922 %16 %

Swine$96$8513 %9 %

Contract Manufacturing and Other (2) $19$1258 %

Total Revenue$1,371$1,19315 %10 %

Gross Profit$785$68415 %

Reported Net Income$57$67(15)%

Adjusted EBITDA$334$27621 %

Reported EPS$0.11$0.13(15)%

Adjusted EPS$0.40$0.378 %

(1) Organic CC Growth = Represents revenue growth excluding royalty revenue that was sold to a third party and the impact of foreign exchange rates.

(2) Primarily represents revenue from arrangements in which we manufacture products on behalf of a third party and royalty revenue. Royalty revenue sold to a third party, to which we are no longer entitled but is still required to be recognized as revenue under GAAP, totaled $9 million for the three months ended March 31, 2026.

In the first quarter of 2026, revenue was $1,371 million, an increase of 15% on a reported basis, or 10% on an organic constant currency basis, compared to the first quarter of 2025.

Pet Health revenue was $710 million, an increase of 12% on a reported basis, or 7% on an organic constant currency basis. The year over year volume increase of 5% in the first quarter was primarily driven by new products, and the addition of two new retail customers benefitting parasiticides. The 2% increase from price was in line with the company's expectation. The Adva

elan-20260224FALSE000173910400017391042026-02-242026-02-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 24, 2026

Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter)

INDIANA

001-38661 82-5497352 (State or other jurisdiction of(Commission File (I.R.S. Employer incorporation)Number) Identification No.)

450 ELANCO CIRCLE

46221

INDIANAPOLIS, INDIANA

(Zip Code) (Address of principal executive offices)

Registrant’s telephone number, including area code: (877) 352-6261

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered Common stock, no par valueELANNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02    Results of Operations or Financial Condition. Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 24, 2026, announcing the results of operations for the full year and fiscal quarter ended December 31, 2025, and guidance for the full year and first quarter of 2026, for Elanco Animal Health Incorporated. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit NumberDescription

99.1Press Release issued by Elanco Animal Health Incorporated dated February 24, 2026

104.1Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ELANCO ANIMAL HEALTH INCORPORATED

Date:February 24, 2026/s/ Robert M. VanHimbergen Robert M. VanHimbergen Executive Vice President and Chief Financial Officer